Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dehydrogenase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    262 result(s) found for: Dehydrogenase. Displaying page 3 of 14.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-002470-40 Sponsor Protocol Number: PROSORA Start Date*: 2017-11-16
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Observational study of the effects of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib (PROSORA-study)
    Medical condition: patients with unresectable hepatocellular cancer, advanced clear-cell renal cell carcinoma, locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004444-31 Sponsor Protocol Number: KWMP001 Start Date*: 2015-01-09
    Sponsor Name:
    Full Title: Effects and consequences for mother and child from treatment for depression A prospective randomized, placebo- controlled, trial with internet-based cognitive behavior therapy and sertraline or...
    Medical condition: Prosepctive randomized two armed study to evaluate moderate depression during pregnancy treated with interbnetbased CBT and sertarline or placebo and longterm outcome in the children.Secondary obj...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001194-29 Sponsor Protocol Number: OSHO #075 Start Date*: 2008-01-11
    Sponsor Name:Universität Leipzig
    Full Title: An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy
    Medical condition: Patients with acute myeloid leukemia not eligible for or resistant to chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001948-19 Sponsor Protocol Number: IM101-603 Start Date*: 2017-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome
    Medical condition: Adults with moderately to severely Active Primary Sjögrens Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    20.1 10010331 - Congenital, familial and genetic disorders 10048676 Sjogren-Larsson syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004055-37 Sponsor Protocol Number: ALXN1830-WAI-201 Start Date*: 2020-05-06
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia
    Medical condition: WAIHA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003956-19 Sponsor Protocol Number: RA101495-01.301 Start Date*: 2019-02-13
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: Phase 3, Multicenter, Open-Label, Single-Arm Study to Confirm the Safety and Efficacy of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001645-40 Sponsor Protocol Number: REPAVID-19 Start Date*: 2020-05-06
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia
    Medical condition: COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002744-74 Sponsor Protocol Number: F3-IROzono-COVID-19 Start Date*: 2022-06-23
    Sponsor Name:Sociedad Española de Ozonoterapia - SEOT [...]
    1. Sociedad Española de Ozonoterapia - SEOT
    2. Cátedra de Ozonoterapia y Dolor Crónico de la Universidad Católica San Antonio de Murcia - UCAM
    Full Title: Effect of rectal ozone therapy on the clinical progress of hospitalized patients with mild-moderate covid19 infection: A triple- blind, randomized controlled trial.
    Medical condition: COVID-19 infection requiring hospitalization
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003350-80 Sponsor Protocol Number: APHP190843 Start Date*: 2020-01-15
    Sponsor Name:Université de Sherbrooke
    Full Title: Lessening Organ Dysfunction with VITamin C (LOVIT)
    Medical condition: Sepsis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000276-41 Sponsor Protocol Number: SUMO Start Date*: 2020-03-05
    Sponsor Name:Erasmus MC
    Full Title: Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor (cimetidine) on the exposure of trifluridine/tipiracil (Lonsurf®) in patients with metastatic colorectal cancer (mCRC).
    Medical condition: patients with mCRC with an indication for lonsurf treatment.
    Disease:
    Population Age: Gender:
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002820-26 Sponsor Protocol Number: ALXN1210-PNH-304 Start Date*: 2017-11-24
    Sponsor Name:Alexion Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2022-002599-35 Sponsor Protocol Number: 2022-1-58-002 Start Date*: 2022-10-21
    Sponsor Name:Centre de Lutte Contre le Cancer Eugène Marquis
    Full Title: Contribution of [18F]DPA-714 PET for grading and exploration of the inflammatory microenvironment of glioma, a pilot study.
    Medical condition: glioma (grade OMS II à IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-004331-23 Sponsor Protocol Number: FNO-RS1-TERIFIN Start Date*: 2023-03-23
    Sponsor Name:Fakultní nemocnice Ostrava
    Full Title: The importance of therapeutic monitoring of teriflunomide and fingolimod in the treatment of multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10064137 Progression of multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005473-10 Sponsor Protocol Number: BEYOND Start Date*: 2021-11-24
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: BEZLOTOXUMAB YIELDED OUTCOMES BY ADDRESSING PERSONALIZED NEEDS IN CLOSTRIDIOIDES DIFFICILE INFECTION: THE BEYOND DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL
    Medical condition: Clostridioides difficile Infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004862 10085158 Clostridioides difficile infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000164-93 Sponsor Protocol Number: 1000000 Start Date*: 2006-05-10
    Sponsor Name:Department of Anesthesiology University Hospital Center
    Full Title: Effect of Nutritional Support on Liver Integrity during General Anesthesia for Laparoscopic Cholecystectomy. A Pilot Study
    Medical condition: To the best of our knowledge, there is no clinical study on the protective effect of nutritional support on the liver in the perioperative setting using clinical and biological variables. Regarding...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002370-39 Sponsor Protocol Number: ALXN1210-PNH-303 Start Date*: 2019-07-02
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxys...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) SE (Completed) FI (Completed) CZ (Completed) ES (Ongoing) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000101-37 Sponsor Protocol Number: IM128-035 Start Date*: 2017-04-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary ...
    Medical condition: subjects with moderate to severe Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040766 Sjogren's disease LLT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10042846 Syndrome Sjogren's LLT
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10040765 Sjogren's LLT
    19.1 10010331 - Congenital, familial and genetic disorders 10048676 Sjogren-Larsson syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007265-20 Sponsor Protocol Number: IPH1101-205 Start Date*: 2008-03-06
    Sponsor Name:Innate Pharma
    Full Title: A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients wit...
    Medical condition: metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001431-56 Sponsor Protocol Number: NUT-2/PBC Start Date*: 2022-03-07
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patien...
    Medical condition: primary biliary cholangitis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) FI (Prematurely Ended) BE (Completed) FR (Completed) NO (Prematurely Ended) NL (Completed) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016636-13 Sponsor Protocol Number: 113173 Start Date*: 2010-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients...
    Medical condition: First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 14:16:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA